| Segment Reporting – Pharmaceuticals |
|
XLS | ||||||
|
|
|
|
|
|
|
| ||
|
|
Merck Serono |
Consumer Health Care |
Pharmaceuticals | |||||
|
EUR million |
Q1 |
Q1 |
Q1 |
Q1 |
Q1 |
Q1 | ||
| ||||||||
|
Sales |
1,344.9 |
1,336.3 |
116.2 |
106.9 |
1,461.2 |
1,443.2 | ||
|
Royalty, license and commission income |
82.3 |
70.5 |
0.3 |
0.7 |
82.6 |
71.2 | ||
|
Total revenues |
1,427.2 |
1,406.8 |
116.6 |
107.6 |
1,543.8 |
1,514.4 | ||
|
Gross margin |
1,221.6 |
1,186.5 |
82.1 |
72.8 |
1,303.7 |
1,259.4 | ||
|
Marketing and selling expenses |
–351.7 |
–322.2 |
–60.6 |
–56.8 |
–412.3 |
–379.0 | ||
|
Royalty, license and commission expenses |
–106.3 |
–116.9 |
–0.4 |
–0.2 |
–106.7 |
–117.0 | ||
|
Administration expenses |
–62.5 |
–62.3 |
–6.0 |
–5.9 |
–68.5 |
–68.3 | ||
|
Other operating expenses and income |
–48.0 |
–65.1 |
–1.5 |
–2.6 |
–49.5 |
–67.7 | ||
|
Research and development |
–305.6 |
–304.4 |
–4.8 |
–4.8 |
–310.5 |
–309.3 | ||
|
Operating result |
148.4 |
178.0 |
7.7 |
1.5 |
156.1 |
179.5 | ||
|
Exceptional items |
1.0 |
– |
– |
– |
1.0 |
– | ||
|
Earnings before interest and tax (EBIT) |
149.4 |
178.0 |
7.7 |
1.5 |
157.1 |
179.5 | ||
|
Net operating assets* |
9,962.2 |
10,359.7 |
306.8 |
310.8 |
10,269.0 |
10,670.5 | ||
|
Segment liabilities* |
–1,229.0 |
–1,268.9 |
–79.9 |
–86.4 |
–1,308.8 |
–1,355.3 | ||
|
Capital spending on property, plant and equipment |
44.8 |
46.0 |
0.6 |
1.4 |
45.5 |
47.4 | ||
|
Investments in intangible assets |
5.1 |
11.5 |
0.1 |
0.3 |
5.2 |
11.8 | ||
|
Depreciation and amortization |
–199.4 |
–181.8 |
–2.6 |
–2.8 |
–202.1 |
–184.5 | ||
|
Impairment losses |
–50.4 |
–17.2 |
– |
– |
–50.4 |
–17.2 | ||
|
Net cash flows from operating activities |
340.8 |
246.1 |
13.8 |
–1.2 |
354.5 |
244.9 | ||
|
Net cash flows from investing activities |
197.4 |
–54.7 |
–0.8 |
–1.3 |
196.7 |
–56.0 | ||
|
Free cash flow |
538.2 |
191.4 |
13.0 |
–2.5 |
551.2 |
188.9 | ||
|
Underlying free cash flow |
273.1 |
191.4 |
13.0 |
–2.5 |
286.1 |
188.9 | ||
|
FCR in % |
19.1 |
13.6 |
11.2 |
–2.3 |
18.5 |
12.5 | ||
|
ROS in % |
10.4 |
12.7 |
6.6 |
1.4 |
10.1 |
11.9 | ||
| Segment Reporting – Chemicals* |
XLS | |||||||||
|
|
|
|
|
|
|
| ||||
|
|
Merck Millipore |
Performance Materials |
Chemicals | |||||||
|
EUR million |
Q1 |
Q1 |
Q1 |
Q1 |
Q1 |
Q1 | ||||
| ||||||||||
|
Sales |
608.4 |
228.2 |
408.0 |
351.4 |
1,016.4 |
579.6 | ||||
|
Royalty, license and commission income |
2.9 |
1.4 |
0.7 |
3.5 |
3.6 |
4.9 | ||||
|
Total revenues |
611.3 |
229.6 |
408.7 |
354.9 |
1,020.0 |
584.5 | ||||
|
Gross margin |
356.3 |
127.0 |
264.2 |
225.9 |
620.4 |
352.9 | ||||
|
Marketing and selling expenses |
–146.1 |
–57.7 |
–32.6 |
–30.5 |
–178.8 |
–88.2 | ||||
|
Royalty, license and commission expenses |
–3.1 |
–1.7 |
–1.5 |
–3.5 |
–4.6 |
–5.2 | ||||
|
Administration expenses |
–28.2 |
–10.5 |
–8.7 |
–9.3 |
–36.9 |
–19.8 | ||||
|
Other operating expenses and income |
–27.1 |
–14.8 |
–15.1 |
–18.3 |
–42.3 |
–33.1 | ||||
|
Research and development |
–32.6 |
–6.8 |
–36.5 |
–31.3 |
–69.0 |
–38.1 | ||||
|
Operating result |
72.0 |
35.2 |
168.8 |
131.5 |
240.8 |
166.7 | ||||
|
Exceptional items |
– |
– |
157.0 |
– |
157.0 |
– | ||||
|
Earnings before interest and tax (EBIT) |
72.0 |
35.2 |
325.8 |
131.5 |
397.8 |
166.7 | ||||
|
Net operating assets** |
6,208.5 |
6,435.6 |
1,312.4 |
1,289.8 |
7,520.8 |
7,725.3 | ||||
|
Segment liabilities** |
–324.3 |
–361.4 |
–143.1 |
–166.8 |
–467.4 |
–528.2 | ||||
|
Capital spending on property, plant |
16.0 |
7.9 |
13.3 |
9.2 |
29.3 |
17.1 | ||||
|
Investments in intangible assets |
1.0 |
0.7 |
0.8 |
0.6 |
1.7 |
1.3 | ||||
|
Depreciation and amortization |
–72.0 |
–11.6 |
–27.0 |
–23.4 |
–99.0 |
–35.0 | ||||
|
Impairment losses |
– |
– |
– |
–9.0 |
– |
–9.0 | ||||
|
Net cash flows from operating activities |
65.6 |
30.0 |
116.9 |
115.6 |
182.5 |
145.6 | ||||
|
Net cash flows from investing activities |
–14.1 |
–10.4 |
181.6 |
–8.9 |
167.6 |
–19.3 | ||||
|
Free cash flow |
51.5 |
19.6 |
298.6 |
106.7 |
350.1 |
126.3 | ||||
|
Underlying free cash flow |
57.8 |
19.6 |
97.6 |
106.7 |
155.4 |
126.3 | ||||
|
FCR in % |
9.5 |
8.5 |
23.9 |
30.1 |
15.2 |
21.6 | ||||
|
ROS in % |
11.8 |
15.3 |
41.3 |
37.1 |
23.6 |
28.5 | ||||
| Segment Reporting – Corporate and Other/Merck Group |
XLS | |||||
|
|
|
|
|
| ||
|
|
Corporate and Other |
Merck Group | ||||
|
EUR million |
Q1 |
Q1 |
Q1 |
Q1 | ||
| ||||||
|
Sales |
– |
– |
2,477.5 |
2,022.8 | ||
|
Royalty, license and commission income |
– |
– |
86.2 |
76.1 | ||
|
Total revenues |
– |
– |
2,563.8 |
2,098.9 | ||
|
Gross margin |
– |
– |
1,924.1 |
1,612.2 | ||
|
Marketing and selling expenses |
–0.5 |
–1.1 |
–591.6 |
–468.2 | ||
|
Royalty, license and commission expenses |
– |
– |
–111.3 |
–122.2 | ||
|
Administration expenses |
–19.5 |
–16.3 |
–124.9 |
–104.4 | ||
|
Other operating expenses and income |
–5.3 |
–34.2 |
–97.1 |
–134.9 | ||
|
Research and development |
– |
0.1 |
–379.5 |
–347.2 | ||
|
Operating result |
–25.3 |
–51.5 |
371.6 |
294.8 | ||
|
Exceptional items |
– |
– |
158.0 |
– | ||
|
Earnings before interest and tax (EBIT) |
–25.3 |
–51.5 |
529.5 |
294.8 | ||
|
Net operating assets* |
66.8 |
74.7 |
17,856.6 |
18,470.5 | ||
|
Segment liabilities* |
–11.7 |
–14.9 |
–1,787.9 |
–1,898.4 | ||
|
Capital spending on property, plant and equipment |
0.1 |
0.1 |
74.9 |
64.7 | ||
|
Investments in intangible assets |
2.4 |
0.9 |
9.3 |
14.0 | ||
|
Depreciation and amortization |
–1.5 |
–0.6 |
–302.5 |
–220.2 | ||
|
Impairment losses |
– |
– |
–50.4 |
–26.2 | ||
|
Net cash flows from operating activities |
252.1 |
–111.8 |
284.9 |
278.7 | ||
|
Net cash flows from investing activities |
259.9 |
1,344.8 |
104.3 |
1,269.5 | ||
|
Free cash flow |
255.9 |
–120.4 |
645.3 |
194.8 | ||
|
Underlying free cash flow |
255.9 |
–108.6 |
185.6 |
206.6 | ||
|
FCR in % |
– |
– |
7.2 |
9.8 | ||
|
ROS in % |
– |
– |
14.5 |
14.0 | ||